ASX RELEASE: EIQ **6 June 2024**

Artificial Intelligence Improves Identification of High-Risk Aortic Stenosis - Independent Validation

- **Benefits of the company's AI presented at the 'New York Valves' Structural Heart Summit 2024 by Dr. Pedro Covas (Baylor Scott & White)**
- **Findings follow a seven-month deployment in a real-world hospital setting to determine the technology's effectiveness**
- **EchoSolv-AS identified significantly more patients with severe AS vs human-only diagnosis**

Sydney: Artificial Intelligence and Medical Technology company Echo IQ ("the Company") (ASX:EIQ) is pleased to advise that earlier today, Dr. Pedro Covas (Baylor Scott & White, The Heart Hospital Plano TX) delivered the scientific presentation: **AI-Powered Cardiac Ultrasound Improves Identification of High-Risk Aortic Stenosis (Echo IQ)** at New York Valves (Structural Heart Summit).

Dr. Covas highlighted the need for an artificial intelligence ("AI") system for aortic stenosis. He revealed that the condition is underdiagnosed and undertreated worldwide, partly due to the complexity in the diagnosis of severe aortic stenosis (including low-flow states), and that there is a need for assistance to improve rates of diagnosis.

The independent research presented by Dr. Covas considered whether AI could improve accuracy and reproducibility of diagnosis of severe aortic stenosis in a real-world hospital setting. To test this, Echo IQ's technology (EchoSolv-AS) was applied to the echocardiographic report data of an academic heart hospital (within the Baylor Scott & White network) over a seven-month period with a subset of the assessments adjudicated via comprehensive image review by expert cardiographers.

The findings showed EchoSolv to be successful in identifying more patients at risk of aortic stenosis than human-only diagnosis. Specifically:

- EchoSolv accurately identified 15% more patients with severe aortic stenosis than human-only diagnosis
- Where initial underdiagnosis occurred, patients were found to have a "low flow" state of disease in 30% of cases (subsequently identified by EchoSolv)

The research concluded that:

1. Echo IQ's technology can automatically identify aortic stenosis patients at-risk using only echocardiographic measurement data
2. Echo IQ's technology has the potential to improve diagnostic rates of severe aortic stenosis, particularly in low flow states
3. There are important implications for less specialised cardiology centres, where echocardiographers are likely to benefit the most from automated diagnosis of severe AS

Echo IQ Chief Medical Advisor, Professor David Playford said: *"This kind of independent research demonstrates exactly how Echo IQ's artificial intelligence can help healthcare professionals identify patients with severe cases of aortic stenosis as well as those with significant risk of disease. Diagnosing aortic stenosis accurately, and in a timely fashion, is extremely complex and the findings shared by Dr. Covas show clearly how Echo IQ's artificial intelligence can help improve clinical performance."*

Echo IQ Executive Chairman, Andrew Grover said*: "We are extremely pleased to see the power of our AI being highlighted in a scientific conference of this calibre. Independent validation like this clearly demonstrates the kind of impact EchoSolv can have in healthcare settings. Given we expect FDA Clearance for our AI-enabled solution for Aortic Stenosis in only 8 weeks or so, we are looking forward to seeing EchoSolv start to gain commercial traction at a significantly accelerated rate."*

-ENDS-

Media Enquiries:
Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investors@echoiq.ai

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.